Publications by authors named "R Murru"
Article Synopsis
- The study evaluated the safety and effectiveness of rituximab biosimilars compared to the original rituximab (Mabthera) in 800 patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia across 13 centers in Italy.
- Out of 505 newly diagnosed patients analyzed, 16.8% experienced adverse drug reactions (ADRs), mostly during the first and second infusions, with the common reactions being general disorders and administration site conditions.
- The results indicate that rituximab biosimilars are clinically safe and switching between different biosimilars does not increase adverse events, potentially encouraging wider use and lowering healthcare costs.
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.
Riccardo Bomben Antonella Zucchetto Roberta Laureana Annalisa Chiarenza Jacopo Olivieri Roberta Murru
Hemasphere
July 2024